Get the Stockscreener App
1,077.75
0.07%
0.77
After Hours:
1075.50
-2.25
-0.21%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,077.75, with a volume of 1.01M.
It is up +0.07% in the last 24 hours and down -2.41% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,076.98
Open:
$1076.98
24h Volume:
1.01M
Relative Volume:
0.27
Market Cap:
$964.61B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
53.30
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
+0.59%
1M Performance:
-2.41%
6M Performance:
+35.55%
1Y Performance:
+35.71%
1-Day Range:
$1,068.30
$1,081.39
1-Week Range:
$1,063.00
$1,088.48
52-Week Range:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,077.75 | 963.92B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.63 | 500.60B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.98 | 406.30B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
139.18 | 266.48B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
106.78 | 264.21B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Why Eli Lilly’s Mounjaro Is Reshaping Obesity Care — and the LLY Stock Story Behind It - AD HOC NEWS
Why Eli Lilly Is the Unexpected Must-Buy Dividend Powerhouse to Own in 2026 - 24/7 Wall St.
Eli Lilly and Company $LLY Holdings Decreased by Nvwm LLC - MarketBeat
Regent Peak Wealth Advisors LLC Purchases Shares of 2,667 Eli Lilly and Company $LLY - MarketBeat
Highland Capital Management LLC Decreases Stake in Eli Lilly and Company $LLY - MarketBeat
Institutional Investors Double Down on Eli Lilly’s Growth Trajectory - AD HOC NEWS
Beacon Investment Advisory Services Inc. Cuts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Inside Eli Lilly’s Obesity Revolution: How Mounjaro Is Rewriting the Weight-Loss Market — and th - AD HOC NEWS
AMI Asset Management Corp Sells 1,020 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly’s Growth Trajectory Bolstered by Landmark Government Agreement - AD HOC NEWS
3 Drug Stocks to Buy at a Discount - The Motley Fool
Eli Lilly’s Strategic Moves Cement Its Market Leadership - AD HOC NEWS
Cwm LLC Has $75.20 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Busey Bank Purchases 8,338 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly (LLY) a Top Stock Split Candidate in 2026 - TipRanks
Eli Lilly Stock (LLY) Holds Near $1,078 After Friday’s Close as GLP‑1 Pricing, Pill Competition, and Retatrutide Data Shape the 2026 Outlook - ts2.tech
Eli Lilly Stock (LLY) Today: GLP‑1 Price Cuts, the Obesity Pill Race, and What Investors Are Watching Into 2026 - ts2.tech
Eli Lilly's New Drug Data Sets Up a High-Stakes 2026 - Finviz
Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026 - Yahoo Finance
Eli Lilly’s Strategic Moves in the Oral Obesity Drug Race - AD HOC NEWS
Eli Lilly (LLY) and Novo Nordisk (NVO) Drugs Impact Grocery Spen - GuruFocus
2025 Newsmaker: David Ricks - Indianapolis Business Journal
United States Semaglutide Market Forecast and Company Analysis Report 2025-2033 Featuring Novo Nordisk, Eli Lilly and Co, AstraZeneca, Biocon, Johnson and Johnson, Pfizer, AbbVie, and SanofiResearchAndMarkets.com - The AI Journal
Swedbank AB Grows Holdings in Eli Lilly and Company $LLY - MarketBeat
Private Trust Co. NA Sells 2,448 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Navigates Strategic Moves and Mounting Competition - AD HOC NEWS
ABL Bio Secures $55 Mln R&D Funding From Eli Lilly - Nasdaq
Eli Lilly Navigates a Pivotal Year for Weight-Loss Drug Market - AD HOC NEWS
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly - WV News
Eli Lilly (LLY) Stock: Key News, Catalysts, Forecasts and Risks to Watch Before the Dec. 26, 2025 Market Open - ts2.tech
Eli Lilly’s Stock Holds Firm in the Weight-Loss Market Battle - AD HOC NEWS
Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle? - The Motley Fool
Eli Lilly (LLY) Stock After Hours Today (Dec. 25, 2025): Holiday Pause, GLP‑1 Catalysts, and What to Watch Before the Market Opens Dec. 26 - ts2.tech
Plancorp LLC Sells 1,287 Shares of Eli Lilly and Company $LLY - MarketBeat
OLD National Bancorp IN Has $479 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly’s Valuation Under Scrutiny Amid Shifting Competitive Landscape - AD HOC NEWS
Bollywood star endorsements, prices plummet by 40%! Eli Lilly and Co and Novo-Nordisk A/S intensify competition in India's weight-loss drug market. - 富途牛牛
Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen - ts2.tech
NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly? - Yahoo Finance
Check out Eli Lilly and's stock price (LLY-CA) in real time - CNBC
Eli Lilly (LLY) Bolsters Position in India's Obesity Drug Market - GuruFocus
HBK Sorce Advisory LLC Boosts Stock Position in Eli Lilly and Company $LLY - MarketBeat
16,522 Shares in Eli Lilly and Company $LLY Bought by Roffman Miller Associates Inc. PA - MarketBeat
Novo and Lilly: FDA Approval of Wegovy Pill Launches New Obesity Battle - Morningstar Canada
Eli Lilly and Company $LLY Stock Position Decreased by Exchange Traded Concepts LLC - MarketBeat
Lilly vs. Novo Nordisk: Who Will Lead India’s Growing Obesity-Drug Market? - TipRanks
Lilly, Novo lock horns in India's obesity drug race - Reuters
Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus - Benzinga
What's Going On With Eli Lilly Stock Today? - Benzinga
The Zacks Analyst Blog Highlights Eli Lilly, Shell, ICICI Bank, Frequency Electronics and Vaso - Yahoo Finance
Eli Lilly Navigates Expansion and Intensifying Rivalry - AD HOC NEWS
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):